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Dear Editor,
The coronavirus disease 2019 (COVID-19) emerged in 
Wuhan, Hubei province, China, in November 2019, and 
spread to multiple countries, leading the World Health 
Organization (WHO) to declare it a pandemic on March 11, 
2020. As of June 20, 2020, 8 766 887 cases and 462 706 deaths 
had been reported, with a case fatality rate (CFR) of 5.3% 
worldwide.1 While a crude CFR of COVID-19 in Japan was 
reportedly similar at 5.3% on June 20, 2020,1 the CFR reported 
from different regions of the world vary widely, partly due to 
differences in the healthcare capacity and thoroughness of 
the crisis response and extent and progress of the epidemic.2 
Administration of real-time reverse transcription polymerase 
chain reaction (RT-PCR) testing for potential COVID-19 
patients and their surveillance and tracking are considered as 
the key response.1 
In this regard, Japan’s situation is unique considering the 
initial intense opposition against the broad implementation of 
RT-PCR testing among authorities, primarily because of the 
reliability of RT-PCR testing. As a plausible explanation, there 
had been persistent concerns that the Japanese government 
may have intentionally limited the number of RT-PCR testing 
in Japan; the government initially limited testing to severe 
cases, returnees from abroad, and those who had come in 
close contact with the infected, while avoiding testing the 
remaining population, including asymptomatic individuals 
and those with mild conditions. Therefore, despite increasing 
recognition that an aggressive RT-PCR testing strategy is 
advisable with some limitations in March, it was only after 
Japan officially announced the postponement of Tokyo 2020 
Olympic Games that RT-PCR testing increased in the country, 
although a causal relationship underlying this is unclear. At 
present, eligibility for RT-PCR is still determined by non-
physician staff at local health centers after consultation from 
attending physicians. As a result, only 17 740 COVID-19 
cases were reported as of June 20, 2020 in Japan,1 which is a 
relatively small number considering its population of 125.9 
million people.3 Further, the number of RT-PCR testing in 
Japan (2.63/1000 persons) remained considerably lower than 
the average number of PCR testing in the Organisation for 
Economic Co-operation and Development (OECD) countries 
(60.56/1000 persons) from June 5 to 13 (data from France and 
South Korea are not available).4
To discuss the appropriate number of RT-PCR testing, 
broader contexts of this topic should be recognized. For 
example, the case of quarantine imposed on the cruise ship 
“Diamond Princess,” off the coast of Japan for 14 days (from 
February 5 to 19, 2020), could provide important information 
regarding the ongoing COVID-19 pandemic,5,6 considering 
that a large proportion of the 3711 cruise ship passengers and 
crew members underwent RT-PCR testing for COVID-19 
(3011 respiratory specimens, with the exact number of 
people who underwent the test unknown), and those infected 
were rigorously tracked.7,8 Notably, approximately half of 
the passengers and crew members who tested positive for 
COVID-19 in the Diamond Princess were asymptomatic. 
According to the latest Japanese government report, there 
were 712 RT-PCR-confirmed cases (19.2% of the 3711 persons 
onboard) by April 30, 2020, of whom only 381 (53.5%) were 
symptomatic, while 331 (46.4%) were asymptomatic.7 
This finding was similar to the finding reported in a 
recent article that reviewed the available evidence on 
asymptomatic severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) infection, in which asymptomatic persons 
presumably accounted for approximately 40% to 45% of 
SARS-CoV-2 infections,9 suggesting that the virus can spread 
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silently and widely through human populations. These 
findings are in line with the current notion that a considerable 
proportion of COVID-19 patients remain asymptomatic 
before developing typical symptoms following the natural 
course of the infection. Therefore, an isolation strategy only 
for laboratory-confirmed cases with mild to severe symptoms 
is inadequate for containment. To ensure the security of high-
risk populations (the elderly and those with comorbidities),10 
it is imperative to thoroughly enact countermeasures, such 
as social distancing, quarantine, and isolation, against the 
spread of COVID-19, including among asymptomatic and 
pre-symptomatic individuals.11 
Further, among the passengers and crew members with a 
confirmed infection, at least 13 deaths (1.8%) were recorded.8 
Among the deceased passengers, five (38.5%) and four 
(30.8%) were reportedly in their 70s and 80s, respectively 
(the ages of the remaining three [23.1%] are unknown), 
according to the Ministry of Health, Labour and Welfare. 
Crude CFR of the passengers and crew members aboard the 
Diamond Princess was similar to that of Asian countries, 
such as South Korea, Thailand, and Malaysia. In South Korea, 
which set up an extensive testing program for COVID-19, the 
updated CFR was reported to be 2.3% (280/12 373, as of June 
20, 2020).1 Likewise, CFRs of COVID-19 in Malaysia and 
Thailand were reported to be 1.4% and 1.8% (as of June 20, 
2020), respectively. 1
As such, we should recognize that the CFR on the cruise ship 
with a sufficient number of RT-PCR testing was much lower 
than that across Japan (5.3%).12 On Diamond Princess, all 
passengers were subjected to RT-PCR testing 6 days after the 
start of quarantine. By contrast, as shown in the OECD survey 
results, RT-PCR testing had not been fully implemented in 
Japan as of May 2020, and there could be many undiagnosed 
cases.13 The hypothesis can be underpinned by an estimate of 
excess death, which is often used to evaluate whether influenza 
and pneumonia deaths have increased as a result of a flu 
epidemic or not.14 Surprisingly, Japan has seen an increase in 
deaths (1056 persons) from March 1 to April 1, 2020 despite 
the absence of an influenza epidemic this season, suggesting 
that it was likely because of undiagnosed COVID-19 cases.15-17
It is noteworthy that two novel laboratory examinations 
(antigen testing using serum sample and RT-PCR testing using 
saliva sample) were officially introduced in June as alternative 
methods to RT-PCR using nasopharynx sample in Japan. Still, 
it is useless unless those novel methods are widely applied 
to contain the pandemic. To effectively prevent COVID-19 
spread, performing more RT-PCR testing or other testing for 
potentially infected people is crucial, and we call for further 
discussions in academic fields on this matter. Therefore, 
despite decreasing dangers of the COVID-19 pandemic in 
Japan, the relevant stakeholders in the country should be 
aware of the lessons learned from Diamond Princess and 
other countries.
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